Literature DB >> 22970839

The burden associated with neuropathic pain in Western Europe.

Paul C Langley1, Chantal Van Litsenburg, Joseph C Cappelleri, Dawn Carroll.   

Abstract

BACKGROUND: The purpose of this study is to assess the burden of neuropathic pain (NeP) on health-related quality-of-life (HRQoL), health status, employment status, absenteeism and presenteeism, and direct medical costs in Western Europe.
METHODS: Data are from the 2010 National Health and Wellness Survey (NHWS) for five countries in western Europe: the UK, France, Spain, Germany, and Italy. Among subjects who reported experiencing pain in the past month, those who attributed their pain to NeP were compared with those who attributed their pain to another chronic pain condition other than NeP (the latter was the reference group). These two groups were compared on demographic and both pain and non-pain related comorbidities. Generalized linear models were used to estimate the independent contribution of the presence of NeP on: (a) HRQoL (using the SF-12v2); (b) self-reported health status (the first item of the SF-12v2); (c) employment status; (d) absenteeism and presenteeism (using the WPAI questionnaire); and (e) direct medical costs (estimated from self-reported healthcare resource use and unit costs from the literature).
RESULTS: Relative to the chronic pain reference group, subjects with NeP reported a higher prevalence of severe daily pain (38.12% vs 12.67%, p < 0.05), lower labor force participation (39.68% vs 55.56%; p < 0.05), higher prevalence of sleep difficulties (59.14% vs 46.73%; p < 0.05), insomnia (45.61% vs 29.78%; p < 0.05) anxiety (42.42% vs 31.99%; p < 0.05), and depression (35.25% vs 24.03%; p < 0.05). NeP subjects reported higher rates of absenteeism (39.78% vs 21.47%; p < 0.05) and presenteeism (86.48% vs. 66.70%; p < 0.050). Direct medical costs were approximately twice as high compared to non-NeP controls. In addition, >80% of NeP patients reported having other pain conditions. Regression results amplified these findings by indicating the independent contribution of confounding factors on the presence of NeP. LIMITATIONS: The NHWS is an Internet-based survey and may not be representative of the respective country populations if Internet access is limited. Second, respondents are asked to report their experience of pain. Although respondents are asked if their pain condition has been diagnosed by a physician there is no separate clinical confirmation of the presence of pain, pain conditions reported, and the presence of comorbidities.
CONCLUSIONS: The presence of NeP is associated with an increased disease burden in the chronic pain population. This is seen in terms of HRQoL, health status, employment experience, and direct medical costs.

Entities:  

Mesh:

Year:  2012        PMID: 22970839     DOI: 10.3111/13696998.2012.729548

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  43 in total

Review 1.  Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.

Authors:  Stephen D Skaper; Laura Facci; Mariella Fusco; Maria Federica Della Valle; Morena Zusso; Barbara Costa; Pietro Giusti
Journal:  Inflammopharmacology       Date:  2013-11-01       Impact factor: 4.473

Review 2.  Nocturia Work Productivity and Activity Impairment Compared with Other Common Chronic Diseases.

Authors:  Paul S J Miller; Harry Hill; Fredrik L Andersson
Journal:  Pharmacoeconomics       Date:  2016-12       Impact factor: 4.981

3.  Mapping painDETECT, a neuropathic pain screening tool, to the EuroQol (EQ-5D-3L).

Authors:  Joseph C Cappelleri; Vijaya Koduru; E Jay Bienen; Alesia Sadosky
Journal:  Qual Life Res       Date:  2016-08-02       Impact factor: 4.147

4.  Histamine H4 receptor agonist-induced relief from painful peripheral neuropathy is mediated by inhibition of spinal neuroinflammation and oxidative stress.

Authors:  Maria Domenica Sanna; Laura Lucarini; Mariaconcetta Durante; Carla Ghelardini; Emanuela Masini; Nicoletta Galeotti
Journal:  Br J Pharmacol       Date:  2016-11-18       Impact factor: 8.739

Review 5.  To Treat or Not to Treat: The Effects of Pain on Experimental Parameters.

Authors:  Norman C Peterson; Elizabeth A Nunamaker; Patricia V Turner
Journal:  Comp Med       Date:  2017-12-01       Impact factor: 0.982

6.  Socioeconomic value of intervention for chronic pain.

Authors:  Tomoyuki Takura; Masahiko Shibata; Shinsuke Inoue; Yoichi Matsuda; Hironobu Uematsu; Keiko Yamada; Takahiro Ushida
Journal:  J Anesth       Date:  2016-03-22       Impact factor: 2.078

Review 7.  Neuromodulatory treatments for chronic pain: efficacy and mechanisms.

Authors:  Mark P Jensen; Melissa A Day; Jordi Miró
Journal:  Nat Rev Neurol       Date:  2014-02-18       Impact factor: 42.937

8.  Contributions of Comorbid Diabetes to Sleep Characteristics, Daytime Symptoms, and Physical Function Among Patients With Stable Heart Failure.

Authors:  Cynthia Fritschi; Nancy S Redeker
Journal:  J Cardiovasc Nurs       Date:  2015 Sep-Oct       Impact factor: 2.083

9.  Ferroptosis is involved in the development of neuropathic pain and allodynia.

Authors:  Huixing Wang; Xiaodong Huo; Chenyang Han; Jiang Ning; Hongguang Chen; Bo Li; Jingzhi Liu; Wenting Ma; Quanbo Li; Yonghao Yu; Kemei Shi
Journal:  Mol Cell Biochem       Date:  2021-04-17       Impact factor: 3.396

Review 10.  Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis.

Authors:  Nanna B Finnerup; Nadine Attal; Simon Haroutounian; Ewan McNicol; Ralf Baron; Robert H Dworkin; Ian Gilron; Maija Haanpää; Per Hansson; Troels S Jensen; Peter R Kamerman; Karen Lund; Andrew Moore; Srinivasa N Raja; Andrew S C Rice; Michael Rowbotham; Emily Sena; Philip Siddall; Blair H Smith; Mark Wallace
Journal:  Lancet Neurol       Date:  2015-01-07       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.